6. PUBLISHED SEPTEMBER 2007
BACKGROUND
These guidelines outline:
• How to produce a new publication
• Who pays for publications
• The time it takes to produce a new publication
• Distribution of publications
• How to order existing publications
All Invest Australia publications are developed through the Marketing & Communications team (M&C), in
consultation with industry teams, to maintain a strong corporate and professional image. The M&C team
provides design, printing and distribution services, whether for print or electronic distribution.
When planning a publication, it is important to involve the M&C team as early as possible and adhere to
the following guidelines, which cover both the production and distribution of publications.
HOW DO I PRODUCE A NEW PUBLICATION?
1. Obtain your General Manager's approval to produce a new publication.
2. Fill out a publication brief, which determines:
• Messages to communicate
• The audience you want to reach
• Budget and size of publication
• Images to be sourced
• Quantity required (if printed)
• Translations (if required)
• Schedules (design, print, distribution)
• Distribution strategy
3. Meet with the Marketing team to finish completing the publication brief, and then have it
approved by your General Manager.
KEY CONTACTS
Michelle Chant, Manager, Marketing & Communications
Email: michelle.chant@investaustralia.gov.au
Phone: 02 6276 1520
Juliana Fiuza, Assistant Manager, Marketing & Communications
Email: juliana.fiuza@investaustralia.gov.au
Phone: 02 6276 1514
Guidelines for the Production
& Distribution of Publications
DOCUMENTS FORMAT
7.
8.
9. Visit:
Australian Pavilion No. 4534
BIO International Convention,
17-20 June, San Diego
Australian biotechnology is helping
to make the world a healthier place.
The Nobel Prize-winning discovery of
the causal link between bacteria and
stomach ulcers is just one in a series of
Australian biotechnology is helping
to make the world a healthier place.
The Nobel Prize-winning discovery of
the causal link between bacteria and
stomach ulcers is just one in a series of
Australian biotechnology is helping
to make the world a healthier place.
The Nobel Prize-winning discovery of
the causal link between bacteria and
stomach ulcers is just one in a series of
Australian biotechnology commercial
success stories generating health
include a vaccine for cervical cancer,
diagnostic and management tools
for asthma and chronic obstructive
Australia’s strength’s are clear:
• Strong drug development pipeline with
154 compounds known to be in human
clinical trials (Phase I to III), with 58%
in Phases II and III.
• Over two-thirds of new clinical trials
announced in Australia in 2007
involved international partners.
• Home to more than 470 core
biotechnology companies – 49%
1. Bioshares, 2008 2. Bioshares, 2008 3. Ernst & Young Report, 2006 4. Hopper and Thorburn, 2008
Au Str Al IA At A gl ANCe
• US$35 billion market cap of
life sciences companies as at
31 December 2007. 1
• Over US$850 million of capital
raised in 2007, a 50% increase
on 2006.2
•
biotechnology companies. 3
• In 2007, there were 399
alliances announced, and 70%
were with overseas entities. 4
Australian Biotechnology
Helping to heal the world
One discovery at a time
AD
